Cargando…

Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat

INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosello-Molina, V., Hervas Aparisi, A., Simon Blanes, M., Tejera Nuñez, J., Moreno Soldado, E., Meri Abad, I., Sparano Ros, O., Ribera, C., Esteban, M., De Vicente Muñoz, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565950/
http://dx.doi.org/10.1192/j.eurpsy.2022.1193
_version_ 1784809018612514816
author Rosello-Molina, V.
Hervas Aparisi, A.
Simon Blanes, M.
Tejera Nuñez, J.
Moreno Soldado, E.
Meri Abad, I.
Sparano Ros, O.
Ribera, C.
Esteban, M.
De Vicente Muñoz, T.
author_facet Rosello-Molina, V.
Hervas Aparisi, A.
Simon Blanes, M.
Tejera Nuñez, J.
Moreno Soldado, E.
Meri Abad, I.
Sparano Ros, O.
Ribera, C.
Esteban, M.
De Vicente Muñoz, T.
author_sort Rosello-Molina, V.
collection PubMed
description INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones inhibit monoamine transporters which include dopamine, norepinephrine, and serotonin, resulting in increased neurotransmitter synaptic concentration. Ways of administration show wide range regarding latency period. Onset and appearance of symptoms as well as their duration and intensity may fluctuate. A decreasing order of latency (oral, inhaled, sublingual and intravenous) has been reported. α-PHP can result in the appearance of psychiatric symptoms, include among others, intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. OBJECTIVES: The aim of our study was to assess the epidemiology, clinical and legal features regarding Alpha-pyrrolidinohexanophenone (α-PHP). METHODS: Review the current bibliography to upgrade the existing knowledge. -Present assorted cases with diverse clinical features. All cases include variability through psychopathological interview, symptoms assessment and treatment response according to rating scales (PANSS, YMRS). -Evaluate different treatment administration ways during acute phase and after hospital discharge. RESULTS: Differences were observed after hospitalization in the response using diverse rating scales. We used antipsychotics to treat intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. α-PHP had a negative impact on the quality of life of the patients. CONCLUSIONS: α-PHP is a synthetic cathinone with potential risk to mental health and life of users. It is mandatory to implement common legislation all through the European Union to prevent its use and possible implications on population’s mental health. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9565950
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95659502022-10-17 Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat Rosello-Molina, V. Hervas Aparisi, A. Simon Blanes, M. Tejera Nuñez, J. Moreno Soldado, E. Meri Abad, I. Sparano Ros, O. Ribera, C. Esteban, M. De Vicente Muñoz, T. Eur Psychiatry Abstract INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones inhibit monoamine transporters which include dopamine, norepinephrine, and serotonin, resulting in increased neurotransmitter synaptic concentration. Ways of administration show wide range regarding latency period. Onset and appearance of symptoms as well as their duration and intensity may fluctuate. A decreasing order of latency (oral, inhaled, sublingual and intravenous) has been reported. α-PHP can result in the appearance of psychiatric symptoms, include among others, intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. OBJECTIVES: The aim of our study was to assess the epidemiology, clinical and legal features regarding Alpha-pyrrolidinohexanophenone (α-PHP). METHODS: Review the current bibliography to upgrade the existing knowledge. -Present assorted cases with diverse clinical features. All cases include variability through psychopathological interview, symptoms assessment and treatment response according to rating scales (PANSS, YMRS). -Evaluate different treatment administration ways during acute phase and after hospital discharge. RESULTS: Differences were observed after hospitalization in the response using diverse rating scales. We used antipsychotics to treat intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. α-PHP had a negative impact on the quality of life of the patients. CONCLUSIONS: α-PHP is a synthetic cathinone with potential risk to mental health and life of users. It is mandatory to implement common legislation all through the European Union to prevent its use and possible implications on population’s mental health. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565950/ http://dx.doi.org/10.1192/j.eurpsy.2022.1193 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Rosello-Molina, V.
Hervas Aparisi, A.
Simon Blanes, M.
Tejera Nuñez, J.
Moreno Soldado, E.
Meri Abad, I.
Sparano Ros, O.
Ribera, C.
Esteban, M.
De Vicente Muñoz, T.
Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title_full Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title_fullStr Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title_full_unstemmed Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title_short Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
title_sort synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565950/
http://dx.doi.org/10.1192/j.eurpsy.2022.1193
work_keys_str_mv AT rosellomolinav syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT hervasaparisia syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT simonblanesm syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT tejeranunezj syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT morenosoldadoe syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT meriabadi syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT sparanoroso syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT riberac syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT estebanm syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat
AT devicentemunozt syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat